pharma · Crohn's Disease · Ulcerative Colitis (UC)
AbbVie
AbbVie patent portfolio — 4 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 1 Waukegan Road, North Chicago, Illinois 60064, US
- Employees
- 60,084
- Programs
- 0
- Drugs
- 25
- Patents
- 4
AbbVie patents
4 pharmaceutical patents indexed for AbbVie. 0 expire within 24 months.
AbbVie has 4 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
WO 2025221754
UPADACITINIB DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE L'ARTÉRITE À CELLULES GÉANTES
granted -
WO 2025137347
FORMULATIONS DE RISANKIZUMAB À HAUTE CONCENTRATION
granted -
US 2024398790
TREATING SPONDYLOARTHRITIC CONDITIONS WITH UPADACITINIB
granted -
US 2024390367
METHODS OF TREATING VITILIGO WITH UPADACITINIB
granted
Frequently asked questions
How many patents does AbbVie have?
4 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do AbbVie patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.